An observational study in Arrhythmogenic Cardiomyopathy, PKP2-ACM and PKP2-ARVC, sponsored by Lexeo Therapeutics. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 67 Years. Per ClinicalTrials.gov, last updated 2025-11-12.
Sponsored by Lexeo Therapeutics · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 231 studies in Cardiomyopathies with a site in United States — 56 open to participants now, 69 under way, 6 of them phase 3. Cardiomyopathies · United States.
Among the 231 studies in Cardiomyopathies with a site in United States, this one is the 92nd largest by planned enrollment of the 97 observational ones that give a count, is one of 11 that started in 2025, is one of 98 observational ones, reaches primary completion later than 56 of the 67 other live ones, and was the 216th registered.
556 studies on the registry are indexed under Cardiomyopathies; 153 are open to participants now.
Browse Cardiomyopathies studies →56 of the 231 studies in Cardiomyopathies with a site in United States are open now. Recruiting first, the newest first:
Atrium Therapeutics · Sites in United States
Ages 18–65
Eidos Therapeutics, a BridgeBio company · Sites in United States, Singapore, Spain
Ages 18–80
Vanderbilt University Medical Center · Sites in United States
Ages 8–18 · Men only
Old Dominion University · Sites in United States
Ages 18–85
Lexeo Therapeutics · Sites in United States, Brazil, Canada and 6 more countries
Ages 6+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 116 Cardiomyopathies studies recruiting now, 70 (60%) set no upper age limit and 18 (16%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.
This study: 18 Years to 67 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
231 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 29 · Phase 2 32 · Phase 3 20 · Phase 4 13
First in 1996; this study’s year is marked. 11 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 200 across 264 observational studies indexed under Cardiomyopathies.
Median enrollment 42 across the 132 interventional studies, 160 across the 97 observational. Of the 139 that completed or were terminated, 65 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 231 have an industry lead sponsor. The 10 most frequent:
Lexeo Therapeutics is the lead sponsor of 8 studies on the registry; 4 are open to participants now.
Lexeo Therapeutics has 6 studies filed under Cardiomyopathies — fewer than ten, so there is no comparison to draw.
16 of the studies in Cardiomyopathies with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06109181Lexeo TherapeuticsGene Therapy for ACM Due to a PKP2 Pathogenic Variant | 2026-12 |
| NCT04520347University of California, Los AngelesIVTCC 2.0: A Prospective Multicenter Ventricular Tachycardia Catheter Ablation Registry | 2026-12 |
| NCT04843371Tulane UniversityPPG to Predict Ejection Fraction and Other Echographic Data in the General Population | 2026-12 |
| NCT03534726University of PennsylvaniaEdema and Fibrosis CMR Imaging in Cardiomyopathy | 2026-12-31 |
| NCT03049254Mayo ClinicMayo AVC Registry and Biobank | 2027-03 |
Add all 16 to your calendar (.ics) → With an account.
Among the 231 studies in Cardiomyopathies with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this Phase 1/2 long-term follow-up (LTFU) study is to assess the long-term safety and tolerability of LX2020 for the treatment of arrhythmogenic cardiomyopathy (ACM) due to a plakophilin-2 gene (PKP2) pathogenic variant (PKP2-ACM).
GRIT-PKP2 is a Phase 1/2 long-term follow-up (LTFU) study designed to evaluate the long-term safety and tolerability of LX2020 gene therapy for participants with PKP2-ACM who have previously received LX2020 in the parent study, LX2020-01. After completion of Study LX2020-01, participants will roll over into this study LX2020-02 for an additional 4-year long-term observation. No gene therapy will be administered in Study LX2020-02. Efficacy will be assessed as an exploratory objective.
Participants who received LX2020 in Study LX2020-01 will roll over into this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who received LX2020 in Study LX2020-01
Percentage of subjects who experienced at least 1 treatment emergent adverse event (TEAE) and/or 1 treatment emergent serious adverse event (TESAE).
Evaluation of Safety and Tolerability of LX2020
Time frame: 4 years
Selected Exploratory
Change in the frequency of ventricular arrhythmias from baseline.
Time frame: 4 years
Started Aug 2025 (actual). Primary completion is estimated for Aug 2030, 60 months after the start.
Of 141 observational studies under Cardiomyopathies, half reached primary completion within 83 months of starting (the median), counting those still running; a quarter within 34. This study's planned 60 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lexeo Therapeutics